An office‐based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer
OBJECTIVE To report the rapid (5 min) and simple detection of a nuclear matrix protein (NMP) in the urine of patients with bladder cancer, using a newly developed office‐based dot‐enzyme‐linked immunosorbent assay (ELISA). PATIENTS AND METHODS Western blot and specific immunoglobulin‐G antibody were...
Gespeichert in:
| Veröffentlicht in: | BJU international 2005-08, Vol.96 (3), p.334-339 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 339 |
|---|---|
| container_issue | 3 |
| container_start_page | 334 |
| container_title | BJU international |
| container_volume | 96 |
| creator | Attallah, Abdelfattah M. Sakr, Hanem A. Ismail, Hisham Abdel‐Hady, El‐Sayed K. El‐Dosoky, Ibrahim |
| description | OBJECTIVE
To report the rapid (5 min) and simple detection of a nuclear matrix protein (NMP) in the urine of patients with bladder cancer, using a newly developed office‐based dot‐enzyme‐linked immunosorbent assay (ELISA).
PATIENTS AND METHODS
Western blot and specific immunoglobulin‐G antibody were used to identify the urinary NMP marker. Urine samples from 149 patients with bladder cancer and 72 controls were evaluated using the developed dot‐ELISA. The initial responses of 43 patients treated by irradiation were followed using the assay.
RESULTS
The NMP marker was identified in the urine of patients with bladder cancer at 52 kDa (NMP‐52) by Western blot. The dot‐ELISA detected the urinary NMP‐52 marker in 92% of patients with squamous cell carcinoma, 98% with transitional cell carcinoma, and all six of those with adenocarcinoma of the bladder, with a specificity of 94%. The positive and negative predictive values (97% and 94%, respectively) and efficiency (96%) of the dot‐ELISA were high. In addition, the NMP‐52 tumour marker was not detected in the urine of patients who showed a response after radiotherapy.
CONCLUSION
Detecting the urinary NMP‐52 marker using dot‐ELISA would be helpful in the rapid diagnosis and follow‐up of patients with bladder cancer. |
| doi_str_mv | 10.1111/j.1464-410X.2005.05627.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68078607</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68078607</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3977-e4f574826c46f7f0ce5082e00b46c8ac0c70578deb8ce01d34aec6814f18e8693</originalsourceid><addsrcrecordid>eNqNkMtu3CAUhlHVqrn1FSo26W7cgwcDs8gijdomVaRuGqk7hPEhZWTjKWBlZpdH6DP2SYoz08uyLOAIvgM_HyGUQcXKeLuuGBd8wRl8rWqApoJG1LLaPiPHfw6e_65hJY7ISUprgLIhmpfkiAngtazFMdleBjo65y3-fPzRmoQd9cMwhbHz5j6MKXtLTUpmR90YaYcZbfbhnk7RBxN3NEy2RxPpYHL0W7qJY0YfaFPTMm9M9hhyog8-f6Ntb7oOI7UmWIxn5IUzfcJXh_WU3H14_-XqenH7-ePN1eXtwi5XUi6Qu0ZyVQvLhZMOLDagagRoubDKWLASGqk6bJVFYN2SG7RCMe6YQiVWy1PyZn9vifZ9wpT14JPFvjcBxylpoUAqAbKAag_aOKYU0elN9EP5o2agZ-t6rWeheparZ-v6ybreltbXhzemdsDub-NBcwHOD4BJ1vQuFgU-_cOtSlJWF-5izz34Hnf_HUC_-3Q3V8tfLdOgoA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68078607</pqid></control><display><type>article</type><title>An office‐based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Attallah, Abdelfattah M. ; Sakr, Hanem A. ; Ismail, Hisham ; Abdel‐Hady, El‐Sayed K. ; El‐Dosoky, Ibrahim</creator><creatorcontrib>Attallah, Abdelfattah M. ; Sakr, Hanem A. ; Ismail, Hisham ; Abdel‐Hady, El‐Sayed K. ; El‐Dosoky, Ibrahim</creatorcontrib><description>OBJECTIVE
To report the rapid (5 min) and simple detection of a nuclear matrix protein (NMP) in the urine of patients with bladder cancer, using a newly developed office‐based dot‐enzyme‐linked immunosorbent assay (ELISA).
PATIENTS AND METHODS
Western blot and specific immunoglobulin‐G antibody were used to identify the urinary NMP marker. Urine samples from 149 patients with bladder cancer and 72 controls were evaluated using the developed dot‐ELISA. The initial responses of 43 patients treated by irradiation were followed using the assay.
RESULTS
The NMP marker was identified in the urine of patients with bladder cancer at 52 kDa (NMP‐52) by Western blot. The dot‐ELISA detected the urinary NMP‐52 marker in 92% of patients with squamous cell carcinoma, 98% with transitional cell carcinoma, and all six of those with adenocarcinoma of the bladder, with a specificity of 94%. The positive and negative predictive values (97% and 94%, respectively) and efficiency (96%) of the dot‐ELISA were high. In addition, the NMP‐52 tumour marker was not detected in the urine of patients who showed a response after radiotherapy.
CONCLUSION
Detecting the urinary NMP‐52 marker using dot‐ELISA would be helpful in the rapid diagnosis and follow‐up of patients with bladder cancer.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/j.1464-410X.2005.05627.x</identifier><identifier>PMID: 16042726</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>52‐kDa ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Biomarkers, Tumor - urine ; bladder ; Blotting, Western ; diagnosis ; dot‐ELISA ; Electrophoresis, Polyacrylamide Gel ; Enzyme-Linked Immunosorbent Assay ; Female ; follow‐up ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Male ; marker ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; NMP ; Nuclear Matrix-Associated Proteins - urine ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Point-of-Care Systems ; Tumors of the urinary system ; tumour ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - urine ; Urinary system ; Urinary tract. Prostate gland ; urine</subject><ispartof>BJU international, 2005-08, Vol.96 (3), p.334-339</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3977-e4f574826c46f7f0ce5082e00b46c8ac0c70578deb8ce01d34aec6814f18e8693</citedby><cites>FETCH-LOGICAL-c3977-e4f574826c46f7f0ce5082e00b46c8ac0c70578deb8ce01d34aec6814f18e8693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1464-410X.2005.05627.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1464-410X.2005.05627.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16969312$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16042726$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Attallah, Abdelfattah M.</creatorcontrib><creatorcontrib>Sakr, Hanem A.</creatorcontrib><creatorcontrib>Ismail, Hisham</creatorcontrib><creatorcontrib>Abdel‐Hady, El‐Sayed K.</creatorcontrib><creatorcontrib>El‐Dosoky, Ibrahim</creatorcontrib><title>An office‐based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>OBJECTIVE
To report the rapid (5 min) and simple detection of a nuclear matrix protein (NMP) in the urine of patients with bladder cancer, using a newly developed office‐based dot‐enzyme‐linked immunosorbent assay (ELISA).
PATIENTS AND METHODS
Western blot and specific immunoglobulin‐G antibody were used to identify the urinary NMP marker. Urine samples from 149 patients with bladder cancer and 72 controls were evaluated using the developed dot‐ELISA. The initial responses of 43 patients treated by irradiation were followed using the assay.
RESULTS
The NMP marker was identified in the urine of patients with bladder cancer at 52 kDa (NMP‐52) by Western blot. The dot‐ELISA detected the urinary NMP‐52 marker in 92% of patients with squamous cell carcinoma, 98% with transitional cell carcinoma, and all six of those with adenocarcinoma of the bladder, with a specificity of 94%. The positive and negative predictive values (97% and 94%, respectively) and efficiency (96%) of the dot‐ELISA were high. In addition, the NMP‐52 tumour marker was not detected in the urine of patients who showed a response after radiotherapy.
CONCLUSION
Detecting the urinary NMP‐52 marker using dot‐ELISA would be helpful in the rapid diagnosis and follow‐up of patients with bladder cancer.</description><subject>52‐kDa</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - urine</subject><subject>bladder</subject><subject>Blotting, Western</subject><subject>diagnosis</subject><subject>dot‐ELISA</subject><subject>Electrophoresis, Polyacrylamide Gel</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>follow‐up</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Male</subject><subject>marker</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>NMP</subject><subject>Nuclear Matrix-Associated Proteins - urine</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Point-of-Care Systems</subject><subject>Tumors of the urinary system</subject><subject>tumour</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Urinary Bladder Neoplasms - urine</subject><subject>Urinary system</subject><subject>Urinary tract. Prostate gland</subject><subject>urine</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtu3CAUhlHVqrn1FSo26W7cgwcDs8gijdomVaRuGqk7hPEhZWTjKWBlZpdH6DP2SYoz08uyLOAIvgM_HyGUQcXKeLuuGBd8wRl8rWqApoJG1LLaPiPHfw6e_65hJY7ISUprgLIhmpfkiAngtazFMdleBjo65y3-fPzRmoQd9cMwhbHz5j6MKXtLTUpmR90YaYcZbfbhnk7RBxN3NEy2RxPpYHL0W7qJY0YfaFPTMm9M9hhyog8-f6Ntb7oOI7UmWIxn5IUzfcJXh_WU3H14_-XqenH7-ePN1eXtwi5XUi6Qu0ZyVQvLhZMOLDagagRoubDKWLASGqk6bJVFYN2SG7RCMe6YQiVWy1PyZn9vifZ9wpT14JPFvjcBxylpoUAqAbKAag_aOKYU0elN9EP5o2agZ-t6rWeheparZ-v6ybreltbXhzemdsDub-NBcwHOD4BJ1vQuFgU-_cOtSlJWF-5izz34Hnf_HUC_-3Q3V8tfLdOgoA</recordid><startdate>200508</startdate><enddate>200508</enddate><creator>Attallah, Abdelfattah M.</creator><creator>Sakr, Hanem A.</creator><creator>Ismail, Hisham</creator><creator>Abdel‐Hady, El‐Sayed K.</creator><creator>El‐Dosoky, Ibrahim</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200508</creationdate><title>An office‐based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer</title><author>Attallah, Abdelfattah M. ; Sakr, Hanem A. ; Ismail, Hisham ; Abdel‐Hady, El‐Sayed K. ; El‐Dosoky, Ibrahim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3977-e4f574826c46f7f0ce5082e00b46c8ac0c70578deb8ce01d34aec6814f18e8693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>52‐kDa</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - urine</topic><topic>bladder</topic><topic>Blotting, Western</topic><topic>diagnosis</topic><topic>dot‐ELISA</topic><topic>Electrophoresis, Polyacrylamide Gel</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>follow‐up</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Male</topic><topic>marker</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>NMP</topic><topic>Nuclear Matrix-Associated Proteins - urine</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Point-of-Care Systems</topic><topic>Tumors of the urinary system</topic><topic>tumour</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Urinary Bladder Neoplasms - urine</topic><topic>Urinary system</topic><topic>Urinary tract. Prostate gland</topic><topic>urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Attallah, Abdelfattah M.</creatorcontrib><creatorcontrib>Sakr, Hanem A.</creatorcontrib><creatorcontrib>Ismail, Hisham</creatorcontrib><creatorcontrib>Abdel‐Hady, El‐Sayed K.</creatorcontrib><creatorcontrib>El‐Dosoky, Ibrahim</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Attallah, Abdelfattah M.</au><au>Sakr, Hanem A.</au><au>Ismail, Hisham</au><au>Abdel‐Hady, El‐Sayed K.</au><au>El‐Dosoky, Ibrahim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An office‐based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2005-08</date><risdate>2005</risdate><volume>96</volume><issue>3</issue><spage>334</spage><epage>339</epage><pages>334-339</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><abstract>OBJECTIVE
To report the rapid (5 min) and simple detection of a nuclear matrix protein (NMP) in the urine of patients with bladder cancer, using a newly developed office‐based dot‐enzyme‐linked immunosorbent assay (ELISA).
PATIENTS AND METHODS
Western blot and specific immunoglobulin‐G antibody were used to identify the urinary NMP marker. Urine samples from 149 patients with bladder cancer and 72 controls were evaluated using the developed dot‐ELISA. The initial responses of 43 patients treated by irradiation were followed using the assay.
RESULTS
The NMP marker was identified in the urine of patients with bladder cancer at 52 kDa (NMP‐52) by Western blot. The dot‐ELISA detected the urinary NMP‐52 marker in 92% of patients with squamous cell carcinoma, 98% with transitional cell carcinoma, and all six of those with adenocarcinoma of the bladder, with a specificity of 94%. The positive and negative predictive values (97% and 94%, respectively) and efficiency (96%) of the dot‐ELISA were high. In addition, the NMP‐52 tumour marker was not detected in the urine of patients who showed a response after radiotherapy.
CONCLUSION
Detecting the urinary NMP‐52 marker using dot‐ELISA would be helpful in the rapid diagnosis and follow‐up of patients with bladder cancer.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>16042726</pmid><doi>10.1111/j.1464-410X.2005.05627.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2005-08, Vol.96 (3), p.334-339 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68078607 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | 52‐kDa Adult Aged Aged, 80 and over Biological and medical sciences Biomarkers, Tumor - urine bladder Blotting, Western diagnosis dot‐ELISA Electrophoresis, Polyacrylamide Gel Enzyme-Linked Immunosorbent Assay Female follow‐up Humans Investigative techniques, diagnostic techniques (general aspects) Male marker Medical sciences Middle Aged Nephrology. Urinary tract diseases NMP Nuclear Matrix-Associated Proteins - urine Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Point-of-Care Systems Tumors of the urinary system tumour Urinary Bladder Neoplasms - diagnosis Urinary Bladder Neoplasms - urine Urinary system Urinary tract. Prostate gland urine |
| title | An office‐based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T07%3A55%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20office%E2%80%90based%20immunodiagnostic%20assay%20for%20detecting%20urinary%20nuclear%20matrix%20protein%2052%20in%20patients%20with%20bladder%20cancer&rft.jtitle=BJU%20international&rft.au=Attallah,%20Abdelfattah%20M.&rft.date=2005-08&rft.volume=96&rft.issue=3&rft.spage=334&rft.epage=339&rft.pages=334-339&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1111/j.1464-410X.2005.05627.x&rft_dat=%3Cproquest_cross%3E68078607%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68078607&rft_id=info:pmid/16042726&rfr_iscdi=true |